About Natural Biogenex Private Limited
Data last updated: 06 February 2026
Natural Biogenex Private Limited is a private limited company based in Bangalore, Karnataka, India, a subsidiary of Natural Capsules Limited. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 23 August 2020, the company has been in operation for over 6 years.
Registered with ROC Bangalore under CIN U24239KA2020PTC137602.
Capital: an authorised share capital of ₹72.25 Cr and a paid-up capital of ₹68.89 Cr. It is led by directors including Laxminarayan Moondra and Sunil Mundra Laxminarayana.
Last AGM: 04 August 2025. Financial statements filed for year ended 31 March 2025. Office: No. 23 Trident Towers 4Th Floor 100 Feet Road Jayanagar Ii Block, Bangalore, Karnataka, India – 560011.
As per the financials filed for FY 2025, the company reported a revenue of ₹1.44 Cr, a decline of 39% compared to the previous year.
The company has a workforce of approximately 43 employees as per the latest available data. It operates as a subsidiary of Natural Capsules Limited.
As per MCA filings, the company has open charges of ₹77 Cr and satisfied charges of ₹12.5 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website naturalcapsules.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressNo. 23 Trident Towers 4Th Floor 100 Feet Road Jayanagar Ii Block, Bangalore, Karnataka, India – 560011
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Business Activity of Natural Biogenex Private Limited
Natural Biogenex Private Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Natural Biogenex Private Limited
Natural Biogenex Private Limited is audited by P CHANDRASEKAR LLP for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| P CHANDRASEKAR LLP | blur-value | blur-value | blur-value |
Board of Directors of Natural Biogenex Private Limited
Natural Biogenex Private Limited is currently managed by 7 directors, with 7 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Laxminarayan Moondra
Also directs:
Natural Capsules Limited, Mavion Pharmasciences Private Limited, Tajos Investments Private Limited and 1 more
|
Director | 24 Mar 2023 | 3 Years 3 Months | Current |
|
Sunil Mundra Laxminarayana
Also directs:
Natural Capsules Limited, Tajos Investments Private Limited, Square Plus Life Sciences Private Limited and 1 more
|
Managing Director | 23 Aug 2020 | 5 Years 10 Months | Current |
|
Pramod Kasat
Also directs:
Natural Capsules Limited, Advanced Enzyme Technologies Limited, Sai Silks (Kalamandir) Limited and 4 more
|
Director | 08 Feb 2022 | 4 Years 5 Months | Current |
|
Tekkar Yashwanth Prabhu
Also directs:
Natural Capsules Limited, Simplepay Finance Private Limited, Vridhi Finserv Home Finance Limited and 2 more
|
Director | 29 May 2025 | 1 Years 1 Months | Current |
| Ramesh Kannan | Director | 17 Jun 2023 | 3 Years 0 Months | Current |
Financials of Natural Biogenex Private Limited FY 2025 filings available
Natural Biogenex Private Limited reported revenue of ₹1.44 Cr (down 39% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Natural Biogenex Private Limited
As of FY 2023, Natural Biogenex Private Limited's shareholding pattern shows 89.99% by promoters, 10.01% by public shareholders. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Natural Biogenex Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Feb 2022 | State Bank of India | ₹40 Cr | Open |
| 17 Oct 2021 | Hdfc Bank Limited | ₹37 Cr | Open |
| 01 Jul 2024 | Others | ₹12.5 Cr | Satisfied |
Total charge records: 3 View all charges
Employees and EPFO Compliance at Natural Biogenex Private Limited
Natural Biogenex Private Limited has a workforce of 43 employees as of Mar 29, 2024.
Employee Count & EPFO Data of Natural Biogenex Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Natural Biogenex Private Limited
GSTIN & GST Filing Data of Natural Biogenex Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Natural Biogenex Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Natural Biogenex Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Natural Biogenex Private Limited
MSME Payment Delays by Natural Biogenex Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Natural Biogenex Private Limited
Subsidiaries & Group Companies of Natural Biogenex Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Natural Biogenex Private Limited with ownership details.
MCA Filings & Documents of Natural Biogenex Private Limited
MCA Filings & Documents of Natural Biogenex Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Natural Biogenex Private Limited
Recent News on Natural Biogenex Private Limited
Frequently Asked Questions about Natural Biogenex Private Limited
Natural Biogenex Private Limited is an active private limited company in the pharma sector based in Bangalore, Karnataka, India. It was incorporated on 23 August 2020 (6+ years old) and is registered under CIN U24239KA2020PTC137602. The company has 43 employees.
Natural Biogenex Private Limited reported revenue of ₹1.44 Cr for FY 2025 (down 39.00% YoY).
The current directors of Natural Biogenex Private Limited are:
- Laxminarayan Moondra
- Sunil Mundra Laxminarayana
- Raj Kishore Prasad
- Shilpa Burman
- Pramod Kasat
- Tekkar Yashwanth Prabhu
- Ramesh Kannan
The primary industry of Natural Biogenex Private Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Natural Biogenex Private Limited can be reached at the registered office: No. 23 Trident Towers 4Th Floor 100 Feet Road Jayanagar Ii Block, Bangalore, Karnataka, India – 560011, or through the website naturalcapsules.com.
The authorised capital is ₹72.25 Cr, and the paid-up capital is ₹68.89 Cr.